Triple Elimination of Mother-to-Child Transmission of HIV

By Crystal Lubbe

December 3, 2024

The World Health Organization (WHO) Regional Office for Africa has initiated a pivotal effort for triple elimination of HIV in Africa titled “New step in African region’s efforts to eliminate mother-to-child transmission of HIV, syphilis and hepatitis B.” This article outlines key initiatives aimed at combating these infections. Notably, a central focus is the establishment of the Regional Validation Committee, which is essential for overseeing the national validation reports concerning the elimination of mother-to-child transmission (MTCT) of HIV, syphilis, and hepatitis B.

Launch of the Regional Validation Committee

The WHO Regional Office for Africa has established a Regional Validation Committee to verify the national validation reports for the elimination of mother-to-child transmission of HIV, syphilis, and hepatitis B. This committee plays a critical role in ensuring the quality and validity of the elimination reports and certifying countries that meet their goals.

Validation Process

The validation process is transparent and follows standardised criteria and tools. It includes a rigorous assessment at national, regional, and global levels, focusing on significant impact indicators and foundational requirements: data quality, programs, laboratory quality, and community engagement, alongside human rights and gender equality.

Membership and Inaugural Meeting

The Regional Validation Committee comprises experts from countries including Botswana, Cameroon, Ethiopia, Ghana, Kenya, South Africa, Uganda, the United States, and Zimbabwe. The inaugural meeting took place in Brazzaville on November 25-26, 2024.

Commitment and Progress

The committee’s formation highlights the commitment of countries and WHO to help achieve triple infection elimination. The African region has made significant progress against HIV, with over 21.3 million on antiretroviral treatment and 90% of pregnant women in Eastern and Southern Africa receiving therapy to protect infants. Nevertheless, progress remains slow in West and Central Africa.

Role of the Committee

The committee is tasked with reviewing national reports, identifying gaps, and assisting countries in adhering to stringent validation standards. Its aim is to validate and catalyse the development of stronger, more resilient health systems.

Framework and Certification

Guided by WHO’s Framework for Triple Elimination, the committee offers high-burden countries a clear progress roadmap. Notable successes include Botswana achieving silver-tier status for HIV elimination and Namibia’s advancements in hepatitis B and HIV elimination.

Broader Context

The triple elimination agenda fits into broader efforts to reduce disease burden in Africa. Moreover, and importantly, this aligns with global strategies, such as the Global Strategy for Women, Children, and Adolescents’ Health (2016–2030).

In summary, it emphasises the need for the WHO and African nations to eliminate MTCT of HIV. Consequently, it highlights the Regional Validation Committee’s role in validating progress and strengthening health systems across the continent. This endeavor reflects the determination to achieve tangible results in the fight against these infections.

Reference url

Recent Posts

access to medicines
         

Quantifying EU Medicine Access Challenges

🔍 Are we creating a healthcare system that truly works for everyone?

Recent findings from EFPIA shed light on alarming inequities in access to medicines across Europe, showing that only 46% of approved drugs are available to patients this year. With significant delays affecting smaller markets and critical cancer treatments, this article explores the systemic barriers at play and innovative solutions proposed to ensure fair access.

Dive into the full article to uncover how we can collectively shape a more equitable healthcare landscape.

#SyenzaNews #healthcare #MarketAccess

UK Medicine Payment Rates
      

Revitalizing Innovation: The Impact of UK Medicine Payment Rates

💡 Are the UK’s medicine payment rates stifling innovation in life sciences?

Recent analysis reveals that the staggering 23.5% payment rate for pharmaceuticals is not just limiting NHS spending but also curtailing R&D investments, delaying new drug launches, and threatening workforce stability. If we can lower these rates to below 10%, we could unleash significant growth and restore the UK’s competitive edge in the global life sciences landscape.

Discover the critical insights and recommendations that could reshape the future of healthcare in the UK.

#SyenzaNews #healthcarepolicy #innovation

Blinatumomab benefit assessment
            

Blinatumomab Benefit Assessment for ALL and Health Economics

🚀 How does a groundbreaking therapy change the landscape of acute lymphoblastic leukemia treatment?

The recent benefit assessment of Blinatumomab by the German Federal Joint Committee reveals critical insights into its potential as a consolidation therapy for adults with Philadelphia chromosome-negative B-cell precursor ALL. With its orphan drug status promising automatic benefits, the article explores the implications of its high cost and economic impacts, shedding light on the balance needed between innovation and sustainability in healthcare.

Jump into the full analysis to understand how this could impact clinical practice and health economics.

#SyenzaNews #HealthEconomics #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.